Corbus Pharmaceuticals Holdings, Inc.

AI-generated fair value estimate for this company.

Method: Net-cash-plus-risk-adjusted-pipeline approach: $113.68M net cash ($117.94M cash & investments less $4.26M debt) / 19.34M shares = $5.88/share cash floor; plus an estimated $150M risk-adjusted NPV for lead asset CRB-701 (Nectin-4 antibody-drug conjugate, Phase 3 registrational trial in oropharyngeal/cervical cancer), reflecting a ~35% probability-weighted value against an estimated $500M peak-sales-derived un-risked NPV, or $7.76/share; total ~$13.64/share.

Reasoning: Corbus is a clinical-stage, pre-revenue biotech with no sustainable cash flow to discount, so a risk-adjusted net-asset-value framework (hard cash floor plus probability-weighted Phase 3 pipeline NPV) is the standard and more accurate approach versus a conventional FCF DCF.